Brind.

Inflammatix, Inc. receives $41M from ARPA-H for critical care digital twin

3 reports, 1 independent Updated Oct 6
No new developments lately Reached 3 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Inflammatix, Inc. was selected as the commercialization collaborator for a Stanford Medicine-led team and received a $41 million award from the Advanced Research Projects Agency for Health (ARPA-H). This funding is part of the CIRCLE program, which aims to improve care for critically ill patients in intensive care units. Inflammatix will develop a rapid, whole-blood test and commercialize it, which will be paired with a mechanistic digital twin led by Purvesh Khatri.

From newjerseytelegraph.com

Why it matters

Some supportBrind's analysis of the reports

The award supports the development and commercialization of new diagnostic tools and therapeutic guidance systems for critical care medicine. The program is designed to identify a patient's immune subtype in real time, guiding the selection of the most appropriate immunomodulatory therapy.

From newjerseytelegraph.com

Who's involved

  • Purvesh KhatriLeading the mechanistic digital twin component of the ARPA-H funded CIRCLE program.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story